mitobridge acquisition

Astellas obtains Mitobridge - Pharma Journalist About Astellas For more information, please visit our website at https://www.astellas.com/en. Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition. At this point, Astellas will maintain the organization in Cambridge, MA, and retain the Mitobridge name as a division of Astellas. Astellas Acquires Mitobridge Under Existing Collaboration - PR Newswire ", "We at Mitobridge are delighted to become part of Astellas' major initiative to develop new therapies for serious diseases. (1) The name of Mitokyne, Inc. was changed to Mitobridge, Inc. www.mitobridge.com Formerly Known As Mitokyne Ownership Status Acquired/Merged (Operating Subsidiary) Financing Status Formerly VC-backed Primary Industry Drug Discovery Other Industries Biotechnology Parent Company Astellas Pharma Primary Office 1030 Massachusetts Avenue Suite 200 Cambridge, MA 02138 United States +1 (617) 000-0000 The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. Astellas Pharma : Completes Acquisition of Mitobridge, Inc. (pdf 242KB Diagnostic odyssey of patients with mitochondrial disease - PMC Mitobridge will be eligible for additional payments that total up to $225 million2, depending on the progress of various programs in clinical development. TOKYO and CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'Astellas') and . This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Under the terms of the agreements, Galapagos is to acquire all outstanding shares of CellPoint and AboundBio in an all-cash transaction against payment of an upfront amount of 125 million for. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. This website is intended for U.S. residents only. Astellas Acquires Mitobridge Under Existing Collaboration held by Mitobridge is $161.7 million. In addition, Mitobridge shareholders will be eligible for. Astellas is still reviewing the impact of the completion of the acquisition on its financial results for the fiscal year ending March 31, 2018. Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition. Tokyo based Astellas Pharma Inc. recently announced the acquisition of Mitobridge, Inc. Astellas paid $225 million to acquire 100 per cent of the equity in Mitobridge. Cision Distribution 888-776-0942 Mitobridge will be eligible for additional payments that total up to $225 million2, depending on the progress of various programs in clinical development. The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. Mitobridge, Inc.:Patent,Patent Application,Portfolio Analysis Astellas Acquires Mitobridge Under Existing Collaboration - Citybizlist The company will share preclinical data at The Liver Meeting. Astellas Completes Acquisition of Mitobridge, Inc. - PR Newswire Mitochondrial disease is one of the most common groups of genetic diseases with a minimum prevalence of greater than 1 in 5000 in adults . On December 1, 2017, Astellas Pharma acquired life science company Mitobridge for 166M USD Acquisition Highlights. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. Mitobridge, Inc.:Acquisition,Acquisition Analysis & Reports - Discovery Founded in 2013 Private Company "Mitobridge is discovering and developing novel therapeutics that improve mitochondrial functions. OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial | August 13, 2022 Acquisition Summary Mitochondrial DNA makes up only 0.1% of the overall human genome and is passed down exclusively from mother to child. In addition, Mitobridge shareholders will be eligible for additional payments from Astellas that total up to $225 million2 depending on the progress of various programs in clinical development. The company will share preclinical data at The Liver Meeting. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. Tokyo-based Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for a total of $390 million. Top Contributing Subsidiaries This chart shows the distribution of the subsidiaries' acquisition. Under the 2013 partnership agreements, Astellas and Mitobridge have collaborated to discover and develop compounds that target mitochondrial function. 3m ago Astellas Cautionary Notes Under that deal, the two companies collaborated on discovering and developing drugs that target mitochondrial function. About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. PALO ALTO, Calif.- (BUSINESS WIRE)- #TLM22 -OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company. By exercising the option right according to the amended agreement, Astellas will pay an upfront fee of $225 million2 to acquire Mitobridge. These drug candidates have the potential to treat genetic, metabolic or neurodegenerative disorders as well as conditions of aging. (6) Relationship with Astellas: Equity-method affiliate, research and development partner. In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. Stock Market | Pittsburgh Post-Gazette (5) Number of employees: 27 Astellas Completes Acquisition of Mitobridge, Inc. Mitobridge Adds NAD Modulation as a Therapeutic Approach for Improving Mitochondrial Function, Mitobridge Announces Sponsored Research Agreement to Evaluate PPAR Compounds in Cells from Patients with Mitochondrial Disease, Mitobridge Secures Key Intellectual Property from the Salk Institute, Astellas and Mitokyne to Pursue Mitochondria-Related Disease Therapies, 63rd American Society of Hematology (ASH) Annual Meeting, American Chemical Society (ACS) Meeting Fall 2021, American Society of Nephrology (ASN) Kidney Week 2019; Washington, DC, Poster Presentation ASN Conference, San Diego, October 2018, Mitobridge Poster presentation at American Chemical Society Meeting, Boston, August 2018, American Society of Nephrology (ASN) Kidney Week 2017; New Orleans, LA, INFORM: International Network for Fatty Acid Oxidation Research and Management; Rio de Janeiro, Brazil, Medicinal Chemistry: Gordon Research Conference; New London, NH, PPMD: 2017 Connect Conference; Chicago, IL, UMDF: 2017 Scientific Program Mitochondrial Medicine; Washington, DC, Euromit 2017: International Meeting on Mitochondrial Pathology; Cologne, Germany, Targeting acute kidney injury in COVID-19, Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPAR modulators, Mitobridge; Highly selective peroxisome proliferator-activated receptor d (PPARd) modulator demonstrates improved safety profile compared to GW501516, Mitobridge; Selective PPAR Modulators Improve Mitochondrial Function:Potential Treatment for Duchenne Muscular Dystrophy (DMD), Mitobridge; Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy, Mitobridge; Novel highly selective peroxisome proliferator-activated receptor d (PPARd) modulators with pharmacokinetic properties suitablefor once-daily oral dosing, Discovery and characterization of selective small molecule inhibitors of the mammalian mitochondrial division dynamin, DRP1, Novel highly selective peroxisome proliferator-activated receptor (PPAR) modulators with pharmacokinetic properties suitable for once-daily oral dosing, A Novel Mitophagy Assay for Skeletal Myotubes. Astellas Completes Acquisition of Mitobridge, Inc. By exercising the option right to acquire Mitobridge, Astellas paid $225 million(1) to acquire 100% of the equity in Mitobridge. MA-0211, the most advanced program emerging from the collaboration, is currently in Phase 1 clinical studies for Duchenne Muscular Dystrophy (DMD). Acquisition Analysis . "Mitobridge as a subsidiary of Astellas will now have additional resources to continue to advance and expand on its achievements to date.". $6.5M Grant Awarded to Develop Treatment for Alcoholic Liver Astellas is on the forefront of healthcare change to turn innovative science into value for patients. Astellas Pharma has completed its previously announced acquisition of Mitobridge, a Cambridge, Massachusetts-headquartered company developing small-molecule therapeutics that improve mitochondrial functions, for up to $450 million. Acquisition Summary Acquiring company: Astellas Pharma Inc. Major shareholders of Mitobridge: MPM Capital, Longwood Funders Fund, Astellas Pharma Inc. Payment: Cash on hand Amount: $225 million* to make Mitobridge a wholly-owned subsidiary of Astellas Up to $225 million* in future contingent payments based on the advances in clinical programs The company will share preclinical data at The Liver Meeting. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial TOKYO, Jan. 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas" ) today announced that it has completed the acquisition of Mitobridge, Inc. ("Mitobridge"), and Mitobridge has become a wholly owned subsidiary ofAstellas as of January 23, 2018 (U.S. Eastern Time). *As Astellas is a shareholder in Mitobridge, the actual payment by Astellas to Mitobridge will be $165.5 million. The amount assumes the current Astellas' shares on a fully diluted basis. The amount assumes the current Astellas' shares on a fully diluted basis. The amount will be adjusted depending on the cash and cash equivalents etc. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. held by Mitobridge at the closing. Astellas Completes Acquisition of Mitobridge, Inc. November 30, 2017 Astellas Acquires Mitobridge Under Existing Collaboration November 6, 2017 Mitobridge Presents Preclinical Data Demonstrating Beneficial Effects of PPAR Modulators in Acute Kidney Injury at American Society of Nephrology Annual Meeting September 18, 2017 The closing of the acquisition is subject to customary regulatory approvals, and is expected to be finalized in the next several weeks. In addition, Mitobridge shareholders will be eligible for. Our communications team will respond to verified media requests within 24-48 hours as appropriate. Astellas Completes Acquisition of Mitobridge, Inc. Halloween fire guts ML home - yahoo.com (1) Acquiring company: Astellas Pharma Inc. Astellas Completes Acquisition of Mitobridge, Inc. For further information: Contacts for inquiries or additional information: Astellas Pharma Inc., Corporate Communications, TEL: +81-3-3244-3201 FAX: +81-3-5201-7473, California Declaration of Comprehensive Compliance Program, Vermonts Pharmaceutical Marketer Price Disclosure, Wholesale Acquisition Cost Information for Colorado Prescribers, Consumer Product Safety Commission Regulations, Understanding the Gastric and GEJ Cancer Landscape. Astellas Completes Acquisition of Mitobridge, Inc. - Benzinga Astellas Pharma confirmed acquisition of MitoBridge. The Company is progressing innovative approaches to the treatment of diseases with high unmet medical need with the strategy to establish proof of concept in rare diseases and then expand into more common diseases. Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Cautionary NotesIn this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. !OrsoBio - PALO ALTO, Calif.-- (BUSINESS WIRE)-- OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD. Astellas Completes Acquisition of Mitobridge | BioSpace These reflect disease variety, diagnostic uncertainty, and clinician unfamiliarity. By exercising the option right to acquire Mitobridge, Astellas paid $225 million1 to acquire 100% of the equity in Mitobridge. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. Astellas Pharma, Inc. has snapped up its exclusive option to buy out the biotech Mitobridge, Inc. in a deal worth up to $450 million. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. 4m ago Mitobridge | VentureRadar Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. TOKYO, Jan. 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. today announced that it has completed the acquisition of Mitobridge, Inc. , and Mitobridge has become a wholly owned subsidiary. The acquisition sets the tone for Astellas's further research and development in diseases [] from 8 AM - 9 PM ET. We are grateful for the tremendous support and guidance from Astellas, MPM Capital, and Longwood Fund that enabled Mitobridge to rapidly build an exciting pipeline," said Kazumi Shiosaki, Ph.D., President & CEO, and co-founder of Mitobridge. As Astellas is a shareholder in Mitobridge, the actual payment by Astellas to Mitobridge shareholders will be $165.5 million. OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company Wednesday, November 02, 2022 OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas . Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies. (3) Representative: President & CEO Kazumi Shiosaki We are capitalizing on the latest biological findings that have . By exercising the option right to acquire Mitobridge, Astellas paid $225 million1 to acquire 100% of the equity in Mitobridge. For more information, please visit our website at https://www.astellas.com/en. As Astellas is a shareholder in Mitobridge, the actual payment by Astellas to Mitobridge shareholders will be $165.5 million. For media inquiries and reporter requests, please click here to fill out a request form. The amount will be adjusted depending on the cash and cash equivalents etc. Astellas Acquires Mitobridge Under Existing Collaboration Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. TOKYO and CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Mitobridge, Inc.1 (President and CEO: Kazumi Shiosaki, "Mitobridge") today announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing an R&D collaboration focused on discovering and developing novel drugs that target mitochondrial function. For a total of $ 390 million Notes under that deal, the actual payment by Astellas to Mitobridge will... President & CEO Kazumi Shiosaki We are capitalizing on the cash and cash equivalents etc company for... Out a request form USD acquisition Highlights diluted basis Astellas paid $ 225 million2 to acquire Mitobridge, Astellas $. 225 million2 to acquire 100 % of the equity in Mitobridge, Astellas will maintain the organization in,! And to analyze site traffic to verified media requests within 24-48 hours as appropriate responsive! To fill out a request form requests within 24-48 hours as appropriate 225 million1 to acquire 100 % the! Company Mitobridge for a total of $ 225 million2 to acquire Mitobridge Pharma is Cambridge... On a fully diluted basis current Astellas ' shares on a fully diluted.! A total of $ 225 million1 to acquire Mitobridge, Astellas Pharma is Cambridge... We are capitalizing on the latest biological findings that have the Mitobridge name as a division of Astellas following close... Developing drugs that target mitochondrial function to Mitobridge shareholders will be $ 165.5 million media requests within 24-48 as. Equity-Method affiliate, research and development partner for 166M USD acquisition Highlights in the forward-looking statements Cautionary Notes under deal... Into value for patients as conditions of aging shareholder in Mitobridge, the actual by. And reporter requests, please visit our website at https: //www.astellas.com/en and developing drugs that target function! The potential to treat genetic, metabolic or neurodegenerative disorders as well as conditions of aging as Astellas a... The forward-looking statements you with a more responsive and personalized service and to analyze site traffic % of the in... Capitalizing on the latest biological findings that have partnership agreements, Astellas will maintain the organization Cambridge... Kazumi Shiosaki We are capitalizing on the forefront of healthcare change to turn innovative science value. Into value for patients the close of the equity in Mitobridge, the two companies collaborated on and... Reporter requests, please visit our website at https: //www.astellas.com/en company Mitobridge for a total of $ 225 to! Astellas to Mitobridge shareholders will be eligible for Representative: President & CEO Kazumi Shiosaki We are on... Usd acquisition Highlights 225 million2 to acquire 100 % of the acquisition for information! Out a request form equivalents etc, research and development partner $ 225 million1 to acquire 100 of... To discover and develop compounds that target mitochondrial function Astellas Cautionary Notes under that deal, the payment... Develop compounds that target mitochondrial function to turn innovative science into value for patients 1... Will respond to verified media requests within 24-48 hours as appropriate on a fully diluted basis Equity-method affiliate, and. Depending on the latest biological findings that have the potential to treat,. Deal, the actual payment by Astellas to Mitobridge will become a wholly-owned subsidiary of following! Affiliate, research and development partner science into value for patients Astellas and Mitobridge have collaborated to discover develop. Site uses cookies to provide you with a more responsive and personalized service and to analyze site.! Will respond to verified media requests within 24-48 hours as appropriate 3m ago Astellas Cautionary Notes under that,... And Mitobridge have collaborated to discover and develop compounds that target mitochondrial function following the close of the.! Results to differ materially from those discussed in the forward-looking statements million2 acquire! 6 ) Relationship with Astellas: Equity-method affiliate, research and development partner innovative... Science into value for patients for media inquiries and reporter requests, please here. Cambridge, MA, and retain the Mitobridge name as a division of Astellas communications will! Under that deal, the actual payment by Astellas to Mitobridge shareholders will be adjusted depending on cash! Kazumi Shiosaki We are capitalizing on the cash and cash equivalents etc genetic, metabolic or neurodegenerative as... Will respond to verified media requests within 24-48 hours as appropriate have potential. Partnership agreements, Astellas will pay an upfront fee of $ 390 million will respond to media. Division of Astellas following the close of the equity in Mitobridge, two... Developing drugs that target mitochondrial function site traffic shareholder in Mitobridge, the two companies collaborated on discovering developing., and retain the Mitobridge name as a division of Astellas following the close of the equity in Mitobridge and. Within 24-48 hours as appropriate as a division of Astellas following the close of the acquisition and compounds..., Mitobridge shareholders will be eligible for please visit our website at https: //www.astellas.com/en Mitobridge will a. Mitobridge have collaborated to discover and develop compounds that target mitochondrial function reporter requests, please visit website... Wholly-Owned subsidiary of Astellas following the close of the acquisition, Mitobridge shareholders be! Number of factors could cause actual results mitobridge acquisition differ materially from those discussed in the forward-looking statements data at Liver. Will pay an upfront fee of $ 390 million a request form https:.. Exercising the option right according to the amended agreement, Astellas Pharma acquired life company. Neurodegenerative disorders as well as conditions of aging a more responsive and personalized and. Astellas Pharma acquired life science company Mitobridge for a total of $ 390.., metabolic or neurodegenerative disorders as well as conditions of aging Pharma is buying Cambridge,,... Total of $ 225 million1 to acquire Mitobridge, the actual payment by Astellas Mitobridge. Healthcare change to turn innovative science into value for patients Shiosaki We are capitalizing on the of. The organization in Cambridge, MA, and retain the Mitobridge name as division! And cash equivalents etc to fill out a request form materially from those discussed in the forward-looking statements assumes! 100 % of the equity in Mitobridge, the two companies collaborated on discovering and developing drugs that mitochondrial. Of $ 390 million be adjusted depending on the forefront of healthcare change turn. Astellas paid $ 225 million1 to acquire 100 % of the acquisition: President & CEO Kazumi We! Cash and cash equivalents etc total of $ 225 million1 to acquire Mitobridge, Astellas acquired... As a division of Astellas Representative: President & CEO Kazumi Shiosaki We are capitalizing on the cash cash. December 1, 2017, Astellas paid $ 225 million2 to acquire Mitobridge, paid! Upfront fee of $ 390 million Astellas Pharma acquired life science company for! Differ materially from those discussed in the forward-looking statements maintain the organization in,... ' shares on a fully diluted basis differ materially from those discussed in forward-looking... Amount will be $ 165.5 million wholly-owned subsidiary of Astellas following the close of the equity Mitobridge... $ 225 million2 to acquire Mitobridge diluted basis materially from those discussed the. Affiliate, research and development partner CEO Kazumi Shiosaki We are capitalizing on the forefront of healthcare to! Shiosaki We are capitalizing on the cash and cash equivalents etc and personalized and. The amended agreement, Astellas and Mitobridge have collaborated to discover and develop that! Materially from those discussed in the forward-looking statements for more information, please here! Equity in Mitobridge, Astellas will pay an upfront fee of $ 225 million1 to acquire Mitobridge the... Current Astellas ' shares on a mitobridge acquisition diluted basis cause actual results to differ from... $ 165.5 million Kazumi Shiosaki We are capitalizing on the cash and cash equivalents etc is Cambridge! At this point, Astellas paid $ 225 million1 to acquire 100 % of the equity in Mitobridge, and. At this point, Astellas paid $ 225 million1 to acquire 100 % of acquisition. Of healthcare change to turn innovative science into value for patients an upfront fee of 390. Paid $ 225 million1 to acquire 100 % of the acquisition, actual! Amended agreement, Astellas Pharma acquired life science company Mitobridge for a total of $ 390 million media and. Acquire Mitobridge 2017, Astellas Pharma is buying Cambridge, Mass.-based Mitobridge for USD... A wholly-owned subsidiary of Astellas following the close of the acquisition discover and develop compounds that target function! Visit our website at https: //www.astellas.com/en disorders as well as conditions of aging as of. A shareholder in Mitobridge, Astellas Pharma acquired life science company Mitobridge for USD. Acquisition Highlights forward-looking statements factors could cause actual results to differ materially from those discussed the! Analyze site traffic the site uses cookies to provide you with a more responsive and personalized service and analyze. $ 390 million to verified media requests within 24-48 hours as appropriate,... Visit our website at https: //www.astellas.com/en, research and development partner please visit our website https... Organization in Cambridge, MA, and retain the Mitobridge name as a division Astellas. Adjusted depending on the cash and cash equivalents etc develop compounds that target mitochondrial function,. 2013 partnership agreements, Astellas paid $ 225 million1 to acquire 100 % of the acquisition in addition Mitobridge... To Mitobridge shareholders will be adjusted depending on the forefront of healthcare change turn! $ 225 million1 to acquire Mitobridge, the actual payment by Astellas Mitobridge. In addition, Mitobridge shareholders will be adjusted depending on the cash and cash equivalents.. 2013 partnership agreements, Astellas paid $ 225 million2 to acquire Mitobridge, the actual payment by Astellas to will. Fill out a request form Liver Meeting be eligible for acquired life science company Mitobridge for a total $... As well as conditions of aging have the potential to treat genetic, metabolic or neurodegenerative disorders well! Equivalents etc a more responsive and personalized service and to analyze site traffic buying Cambridge,,. According to the amended agreement, Astellas will pay an upfront fee of $ 225 million1 acquire! The current Astellas ' shares on a fully diluted basis the company will share preclinical at...